Azienda Ospedaliera Fatebenefratelli e Oftalmico
Welcome,         Profile    Billing    Logout  
 6 Trials 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cortese, Bernardo
ARMYDA-AMULET, NCT05554822: Head-to-head Comparison of Single Versus Dual Antiplatelet Treatment Strategy After Percutaneous Left Atrial Appendage Closure: a Multicenter, Randomized Study

Recruiting
3
574
Europe
Aspirin 100mg, Aspirin 100 mg OD plus clopidogrel 75 mg OD
Azienda Ospedaliero Universitaria Maggiore della Carita, Abbott Medical Devices
Left Atrial Appendage Occlusion, Antiplatelet Therapy
12/23
12/23
TRANSFORM I, NCT03913832: TReAtmeNt of Small Coronary Vessels: MagicTouch Sirolimus Coated Balloon

Active, not recruiting
N/A
121
Europe
sirolimus drug coated balloon (SCB), paclitaxel releasing coronary balloon catheter
Concept Medicals BV
Coronary Artery Disease, DCB
03/23
09/23
PICCOLETO V, NCT06551662: DCB vs. DES in Bifurcation Coronary Lesions

Not yet recruiting
N/A
321
Europe, RoW
Paclitaxel drug-coated balloons, Sirolimus drug-coated balloons, New generation drug-eluting stent
Fondazione Ricerca e Innovazione Cardiovascolare ETS
Coronary Artery Disease, DCB
02/26
02/28
TRANSFORM II, NCT04893291: Sirolimus-coated Balloon Versus Drug-eluting Stent in Native Coronary Vessels

Recruiting
N/A
1820
Europe, RoW
Everolimus Eluting Stent, Sirolimus Coated Balloon
Fondazione Ricerca e Innovazione Cardiovascolare ETS
Coronary Artery Disease, Coronary Artery Stenosis
11/24
11/28
Verde, Nicla Maria La
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Calendar Jan 2025 - Dec 2025: Pivotal data from ZEST trial for HER2-negative BRCA-mutated or triple-negative breast cancer
Active, not recruiting
3
43
Europe, Canada, Japan, US, RoW
Niraparib, Placebo
GlaxoSmithKline
Neoplasms, Breast
06/24
12/25
YAPPETIZER, NCT03358017: Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer

Completed
2
54
Europe
Zoledronate, zoledronic acid, Atorvastatin 80mg, Standard neoadjuvant cht
Mario Negri Institute for Pharmacological Research, Associazione Italiana per la Ricerca sul Cancro
Triple Negative Breast Cancer
06/21
07/23
GIM28-ELMER, NCT06894173: EvoLution of Neoadjuvant TreatMent in 'Triple-negative' or 'HER-2-positive' Breast Cancer Diagnosed in the EaRly Phase

Recruiting
N/A
1000
Europe
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Breast Cancer
12/25
12/26
PALMARES-2, NCT06805812: Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian Study

Recruiting
N/A
3500
Europe
Palbociclib, Ribociclib, Abemaciclib
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, European Institute of Oncology, Italy, Humanitas Research Hospital IRCCS, Rozzano-Milan, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, OSPEDALE ASST CREMONA, IOV Oncologico Veneto Padova, ASST Fatebenefratelli Sacco, IRCCS Fondazione Salvatore Maugeri, Pavia, Italy, IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori Meldola, Azienda Ospedaliero-Universitaria di Modena, Azienda Ospedaliero-Universitaria Maggiore della Carità di Novara, A.O.U. Federico II, Napoli, San Raffaele University Hospital, Italy, Centro di Riferimento Oncologico - Aviano, Azienda Socio-Sanitaria Territoriale Lariana, Azienda ULSS 3 Serenissima, Ospedale di Mirano, Azienda Ospedaliero Universitaria Policlinico Umberto I, Roma, Fondazione IRCCS Policlinico San Matteo di Pavia, IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Azienda Ospedaliero-Universitaria Careggi, Humanitas, Istituto Clinico Catanese, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Fondazione Policlinico Universitario Campus Bio-Medico, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Breast Adenocarcinoma, Breast Cancer Stage IV, Breast Cancer, Metastatic, Breast Carcinoma, Breast Diseases, Breast Neoplasms, Breast Neoplasms, Male, Breast Cancer, Breast Cancer With Metastatic Bone Disease, Breast Cancers, Breast Neoplasm, Breast Tumors, HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer, HR+ Advanced or Metastatic Breast Cancer, HR+/HER2- Breast Cancer, HRpos Breast Neoplasms, HR-positive, HER2-negative Advanced Breast Cancer, HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer, HR-positive Breast Cancer, Hormone Receptor-Positive Breast Cancer, Hormone Receptor Positive Breast Adenocarcinoma, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Breast Neoplasms, Hormone Receptor Positive HER-2 Negative Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, Hormone Receptor Positive Metastatic Breast Cancer, Hormone Receptor Positive, HER2 Negative Breast Cancer, Hormone Receptor Negative Breast Cancer, Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer, Hormone Receptor Positive Breast Cancer, Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive, HER2-low Neoplasms, Hormone Receptor Positive (HR+), HER2-negative Breast Cancer, Hormone Receptor (HR)-Positive Breast Cancer, Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer, Palbociclib, Ribociclib, Abemaciclib, CDK4/6 Inhibitor, CDK4/6 Inhibitors
12/30
12/40
FIL_PlaLy, NCT06781359: Study on Plasmablastic Lymphoma Patients

Not yet recruiting
N/A
200
Europe
Fondazione Italiana Linfomi - ETS, AIL Roma - Italia, AIL Cuneo - Italia
Plasmablastic Lymphoma
02/28
02/28
Scialdone, Antonio
No trials found
Gaetano, Francesco De
No trials found
Cortese, B
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cortese, Bernardo
ARMYDA-AMULET, NCT05554822: Head-to-head Comparison of Single Versus Dual Antiplatelet Treatment Strategy After Percutaneous Left Atrial Appendage Closure: a Multicenter, Randomized Study

Recruiting
3
574
Europe
Aspirin 100mg, Aspirin 100 mg OD plus clopidogrel 75 mg OD
Azienda Ospedaliero Universitaria Maggiore della Carita, Abbott Medical Devices
Left Atrial Appendage Occlusion, Antiplatelet Therapy
12/23
12/23
TRANSFORM I, NCT03913832: TReAtmeNt of Small Coronary Vessels: MagicTouch Sirolimus Coated Balloon

Active, not recruiting
N/A
121
Europe
sirolimus drug coated balloon (SCB), paclitaxel releasing coronary balloon catheter
Concept Medicals BV
Coronary Artery Disease, DCB
03/23
09/23
PICCOLETO V, NCT06551662: DCB vs. DES in Bifurcation Coronary Lesions

Not yet recruiting
N/A
321
Europe, RoW
Paclitaxel drug-coated balloons, Sirolimus drug-coated balloons, New generation drug-eluting stent
Fondazione Ricerca e Innovazione Cardiovascolare ETS
Coronary Artery Disease, DCB
02/26
02/28
TRANSFORM II, NCT04893291: Sirolimus-coated Balloon Versus Drug-eluting Stent in Native Coronary Vessels

Recruiting
N/A
1820
Europe, RoW
Everolimus Eluting Stent, Sirolimus Coated Balloon
Fondazione Ricerca e Innovazione Cardiovascolare ETS
Coronary Artery Disease, Coronary Artery Stenosis
11/24
11/28
Verde, Nicla Maria La
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Calendar Jan 2025 - Dec 2025: Pivotal data from ZEST trial for HER2-negative BRCA-mutated or triple-negative breast cancer
Active, not recruiting
3
43
Europe, Canada, Japan, US, RoW
Niraparib, Placebo
GlaxoSmithKline
Neoplasms, Breast
06/24
12/25
YAPPETIZER, NCT03358017: Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer

Completed
2
54
Europe
Zoledronate, zoledronic acid, Atorvastatin 80mg, Standard neoadjuvant cht
Mario Negri Institute for Pharmacological Research, Associazione Italiana per la Ricerca sul Cancro
Triple Negative Breast Cancer
06/21
07/23
GIM28-ELMER, NCT06894173: EvoLution of Neoadjuvant TreatMent in 'Triple-negative' or 'HER-2-positive' Breast Cancer Diagnosed in the EaRly Phase

Recruiting
N/A
1000
Europe
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Breast Cancer
12/25
12/26
PALMARES-2, NCT06805812: Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian Study

Recruiting
N/A
3500
Europe
Palbociclib, Ribociclib, Abemaciclib
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, European Institute of Oncology, Italy, Humanitas Research Hospital IRCCS, Rozzano-Milan, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, OSPEDALE ASST CREMONA, IOV Oncologico Veneto Padova, ASST Fatebenefratelli Sacco, IRCCS Fondazione Salvatore Maugeri, Pavia, Italy, IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori Meldola, Azienda Ospedaliero-Universitaria di Modena, Azienda Ospedaliero-Universitaria Maggiore della Carità di Novara, A.O.U. Federico II, Napoli, San Raffaele University Hospital, Italy, Centro di Riferimento Oncologico - Aviano, Azienda Socio-Sanitaria Territoriale Lariana, Azienda ULSS 3 Serenissima, Ospedale di Mirano, Azienda Ospedaliero Universitaria Policlinico Umberto I, Roma, Fondazione IRCCS Policlinico San Matteo di Pavia, IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Azienda Ospedaliero-Universitaria Careggi, Humanitas, Istituto Clinico Catanese, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Fondazione Policlinico Universitario Campus Bio-Medico, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Breast Adenocarcinoma, Breast Cancer Stage IV, Breast Cancer, Metastatic, Breast Carcinoma, Breast Diseases, Breast Neoplasms, Breast Neoplasms, Male, Breast Cancer, Breast Cancer With Metastatic Bone Disease, Breast Cancers, Breast Neoplasm, Breast Tumors, HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer, HR+ Advanced or Metastatic Breast Cancer, HR+/HER2- Breast Cancer, HRpos Breast Neoplasms, HR-positive, HER2-negative Advanced Breast Cancer, HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer, HR-positive Breast Cancer, Hormone Receptor-Positive Breast Cancer, Hormone Receptor Positive Breast Adenocarcinoma, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Breast Neoplasms, Hormone Receptor Positive HER-2 Negative Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, Hormone Receptor Positive Metastatic Breast Cancer, Hormone Receptor Positive, HER2 Negative Breast Cancer, Hormone Receptor Negative Breast Cancer, Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer, Hormone Receptor Positive Breast Cancer, Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive, HER2-low Neoplasms, Hormone Receptor Positive (HR+), HER2-negative Breast Cancer, Hormone Receptor (HR)-Positive Breast Cancer, Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer, Palbociclib, Ribociclib, Abemaciclib, CDK4/6 Inhibitor, CDK4/6 Inhibitors
12/30
12/40
FIL_PlaLy, NCT06781359: Study on Plasmablastic Lymphoma Patients

Not yet recruiting
N/A
200
Europe
Fondazione Italiana Linfomi - ETS, AIL Roma - Italia, AIL Cuneo - Italia
Plasmablastic Lymphoma
02/28
02/28
Scialdone, Antonio
No trials found
Gaetano, Francesco De
No trials found
Cortese, B
No trials found

Download Options